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Mecamylamine pretreatment 
increases subsequent nicotine self-administration 
as indicated by changes in plasma nicotine level 
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Abstract. Acute administration of mecamylamine, a cen- 
trally active nicotinic cholinergic agonist, has been shown 
to increase amount of smoking as indicated by smoking 
topography (e.g., puff rate, puff duration), expired carbon 
monoxide changes, and other inferential measures. In the 
present study, subjects showed significantly greater in- 
creases in plasma nicotine following smoking of two high- 
nicotine research cigarettes when pretreated with mecamyl- 
amine than when pretreated with placebo, even though no 
significant differences in puff volume or puff number were 
detected. Interestingly, none of our subjects reported nau- 
sea, although some achieved plasma nicotine levels at which 
nausea would typically be expected. We attribute the ob- 
served increases in nicotine intake to compensatory behav- 
ior designed to overcome mecamylamine's blocking effects. 
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Mecamylamine is a centrally active nicotinic cholinergic an- 
tagonist with both a competitive and a noncompetitive 
component (Taylor 1980). It has been shown in laboratory 
experiments to block in a dose-related fashion a variety 
of subjective, behavioral, and physiological responses to 
nicotine in both humans and animals. Researchers from 
Jarvik in 1973 to Henningfield in 1984 have in fact argued 
for the potential usefulness of mecamylamine as a therapeu- 
tic agent, and a preliminary clinical trial conducted by Ten- 
nant et al. (1984) found it to be of some help. 
Acute administration of mecamylamine, however, has 
also been shown to increase smoking behavior as reflected 
by topogaphical parameters - e.g., number of cigarettes 
smoked and total number of puffs - and by changes in 
carbon monoxide levels (Domino 1973; Nemeth-Coslett 
et al. 1986; Stolerman et al. 1973). This phenomenon sug- 
gests that smokers may engage in compensatory behavior 
in an attempt to counteract the effects of mecamylamine 
through self-titration. Alternatively, smokers may smoke 
more in order to achieve nicotine-produced relief from dys- 
phoric effects of mecamylamine. In the present study, the 
effects of pretreatment with mecamylamine versus placebo 
upon levels of plasma nicotine were examined in the hopes 
of shedding light on these issues. 
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Materials and methods 
Subjects were 8 male smokers, healthy and not on medica- 
tion, recruited from the community. To be included, they 
had to smoke at least 20 cigarettes per day and to have 
smoked for at least 5 years. Mean age was 45+5 years. 
They had smoked for a mean of 30 ± 5 years and smoked 
a mean of 28 ± 3 cigarettes per day. Mean Fagerstrom Tol- 
erance Questionnaire score was 7 ± 1 and mean plasma co- 
t±nine level 263.6 ± 22.6 ng/ml, characterizing them as mod- 
erately heavy smokers (Pomerleau et al. 1983). 
On 2 days, separated by 1-3 days, subjects reported to 
the laboratory at 10:30 a.m. Blood pressure was measured 
upon arrival and again just before the session as an index 
of mecamylamine activity. Four subjects received 12.5 mg 
mecamylamine PO the 1st day and placebo on the 2nd; 
the rest received placebo first and mecamylamine second. 
(This dose produced the most favorable effects-to-side-ef- 
fects ratio in the pioneering study of Stolerman et al. in 
1973.) An hour later, subjects were asked to smoke one 
usual-brand cigarette to ensure a comparable state of mini- 
mal deprivation. Just before the session, baseline subjective 
measures (Profile of Mood States, Spielberger State Anxiety 
Inventory, and Shiffman Withdrawal Questionnaire) were 
collected. A butterfly infusion set connected to a 1-m line 
was inserted into a left forearm vein; the line was heparin- 
ized and run through a channel in the wall for unobtrusive 
withdrawal of blood. 
Sessions began 90 min after administration of drug or 
placebo. After a 5-rain acclimation period, subjects smoked 
a high-nicotine research cigarette containing 2.9 mg nico- 
tine. A cigarette holder equipped with a pressure transducer 
allowed computerized collection of total puff volume and 
puffnumber.  After 5 rain had elapsed, they smoked another 
high-nicotine cigarette, following which they filled out sub- 
jective forms. Subjects were then asked to dip right hand 
and forearm into a tank of circulating water maintained 
at 3 ° C, depressing a cradle that activated a timer. They 
were requested to nod when they became aware of the pain 
and to remove the arm from the tank when they could 
no longer stand the pain. This procedure served as a marker 
of nicotine activity, since nicotine produces reliable thresh- 
old increases for both awareness and tolerance of pain 
(Pomerleau et al. 1984). Blood samples were withdrawn at 
0, 5, 10, 15, 20, 25, 30, 35, 45, and 55 rain. 
Data were subjected to repeated-measures ANOVA, us- 
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Fig. 1. Mean (_+SEM) base-to-peak plasma nicotine levels after 
two high-nicotine cigarettes following pretreatment with placebo 




























Fig. 2. Individual and mean base-to-peak increases in plasma nico- 
tine levels following two high-nicotine cigarettes after pretreatment 
with placebo or mecamylamine; subjects identified by number 
Results 
Mecamylamine had a marked effect on systolic blood pres- 
sure: Although systolic blood pressure dropped between 
arrival and start of session on both the mecamylamine and 
placebo day, the decrease for mecamylamine was signifi- 
cantly greater than that for placebo [/7(1,7)= 5.23, P <  0.05, 
1-tailed]. Diastolic blood pressure drops were in the ex- 
pected direction though not significant. 
Baseline scores for the Spielberger and four of the six 
POMS subscales showed a tendency, though nonsignificant, 
towards greater dysphoria on the mecamylamine day. Three 
subscales of the Shiffman were scored separately (see Pom- 
erleau et al. 1983); the (generalized) Discomfort subscale 
(querying calmness, concentration, contentedness, tense- 
ness, and irritability) revealed significantly greater dys- 
phoria on the mecamylamine day [t(7)= 2.411, P <  0.05]. 
As shown in Fig. l, base-to-peak elevations of plasma 
nicotine (using min 0 as baseline and peak values deter- 
mined individually for each subject on each day) were sig- 
nificantly greater on the mecamylamine day than on the 
placebo day [F(l,7) = 4.17, P < 0.05, 1-tailed]. Two subjects 
achieved unusually high peak levels of nicotine (111.0 ng/ml 
and 165.0 ng/ml) following mecamylamine pretreatment. 
Subjects varied with respect to how much the mecamyl- 
amine treatment influenced subsequent nicotine intake. Fig- 
ure 2 presents data for individual subjects in terms of their 
base-to-peak difference scores on the placebo day and the 
mecamylamine d a y .  
The observed changes in plasma nicotine were not ac- 
companied by significant differences in either total puff vol- 
ume or total puff number. No systematic subjective changes 
between placebo and mecamylamine conditions were de- 
tected. Likewise, no significant differences were uncovered 
for pain-awareness threshold, endurance threshold, and 
scores on the McGill pain rating scale. No order effects 
were found for any measure. 
Discussion 
The obvious interpretation of the striking increases in plas- 
ma nicotine following mecamylamine pretreatment is that 
subjects were attempting to overcome the blockade, either 
to achieve relief from withdrawal or some other reinforcing 
effect of nicotine. An alternative explanation for the in- 
crease in smoking, as noted above, is that it represented 
an attempt to obtain nicotine-produced relief of mecamyla- 
mine-induced dysphoria. Baseline subjective scores did in 
fact tend to suggest greater dysphoria on the mecamylamine 
day than on the placebo day. It seems doubtful, however, 
that the extremely high plasma nicotine levels observed 
could be accounted for by such an explanation. This conclu- 
sion is supported by the finding of Stolerman et al. (1973) 
that pentolinium, a peripheral nicotinic cholinergic blocker 
used as a control, produced dysphoria equivalent to that 
of mecamylamine without concomitant changes in smoking 
behavior. 
Whether or not subjects succeeded in overcoming the 
mecamylamine blockade cannot be definitively determined; 
more subtle indices of nicotine's psychological effects may 
be needed to settle the question. I f  complete or substantial 
blocking had been achieved, one would expect an initial 
increase in nicotine self-administration to be followed by 
a decrease. This has in fact been shown in monkeys (Gold- 
berg et al. 1983). A similar demonstration over successive 
smoking trials in humans, using differing doses of mecamyl- 
amine and concomitant measures of plasma nicotine, would 
provide additional evidence regarding the clinical and ex- 
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perimental usefulness of  mecamylamine, especially in a self- 
dosing paradigm. 
Following mecamylamine pretreatment, four of  the 
eight subjects reached peak plasma nicotine levels in excess 
of  60 ng/ml, the mean level at which induction of  nausea 
was previously observed in our laboratory (Seyler et al. 
1986), yet none reported nausea nor  showed any objective 
signs of  illness. Interestingly, Spealman and Goldberg, in 
a 1982 study of  schedule-controlled behavior by intrave- 
nous injections of  nicotine in squirrel monkeys, reported 
a similar finding; doses on the order of  300 gg/kg usually 
produced vomiting in these monkeys even at very low levels 
of  responding, whereas in combination with mecamyla- 
mine, vomiting was not  seen. These findings suggest that 
mecamylamine successfully blocked nicotininic cholinergic 
mechanisms involved in nicotine-induced nausea and vom- 
iting and raise the question of  whether exposure to poten- 
tially toxic levels of  nicotine in the absence of  normal self- 
limiting feedback mechanisms constitutes an added risk - 
al though hexamethonium, a quaternary ganglionic blocker, 
and pempidine, like mecamylamine a tertiary compound,  
seem to confer protection from nicotine toxicity in mice 
(Barrass et al. 1969). 
Failure to obtain concomitant  differences in smoking 
topography is surprising, since topographical changes have 
been related to nicotine intake (Herning et al. 1983), and 
since previous findings of  increased smoking following mec- 
amylamine are based on topographical data (e.g., Nemeth- 
Coslett et al. 1986). Possibly with the use of  high-nicotine 
cigarettes, even small differences in depth of  inhalation 
might produce large differences in plasma nicotine levels. 
Indeed, it should be noted that cigarettes making large 
amounts of  nicotine available to the smoker may be re- 
quired to produce the exaggerated elevations observed in 
this study, since smoking of  a usual-brand cigarette 1 h 
after mecamylamine administration failed to produce a dif- 
ference in baseline nicotine measures collected 30 rain later. 
Nevertheless, this outcome sounds a cautionary note with 
regard to relying entirely on topographical data to reach 
conclusions about nicotine intake, particularly in the pres- 
ence of  a pharmacological blocker. 
In summary, the current findings confirm directly, for 
the first time, the inferences of  previous investigators that 
smokers self-administer higher doses of  nicotine after the 
administration of  mecamylamine, at least on an acute basis. 
The extent to which this phenomenon compromises the ef- 
fectiveness of  mecamylamine as a blocker when given at 
safe doses, especially in a nicotine self-dosing paradigm 
where intake cannot be controlled, remains to be estab- 
lished. 
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